GH replacement in hypopituitarism improves lipid profile and quality of life independently of changes in obesity variables

European Journal of Endocrinology

Volumn 159, Issue 6, 2008, Pages 825-832

  Abrams, Pascale ^a,b,h   Boquete, Hugo ^c   Fideleff, Hugo ^c   Feldt Rasmussen, Ulla ^d   Jónsson, Peter J ^e   Koltowska Häggström, Maria ^e,f   Wilton, Patrick ^g   Abs, Roger ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b Sint Vincentiusziekenhuis   (Belgium)

^c Hospital General De Agudos Teodoro Alvarez   (Argentina)

^d Rigshospitalet   (Denmark)

^e PFIZER INC   (United States)

^f UPPSALA UNIVERSITY   (Sweden)

^g KIMS   (United States)

^h Universiteitsplein   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOMATOMEDIN C; TRIACYLGLYCEROL; HUMAN GROWTH HORMONE;

ADULT; ARTICLE; BODY FAT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOPITUITARISM; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; BLOOD; COMPARATIVE STUDY; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL ASPECT;

ADULT; FEMALE; HORMONE REPLACEMENT THERAPY; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; LIPIDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; OBESITY; QUALITY OF LIFE;

EID: 58149343872     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-08-0448     Document Type: Article

References (30)

1. Rosén T & Bengtsson B-Å. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990 336 285-288.
2. Bülow B, Hagmar L, Mikoczy Z, Nordström CH & Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Journal of Clinical Endocrinology and Metabolism 1997 46 75-81.
3. Svensson J, Bengtsson B-Å, Rosén T, Odén A & Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. Journal of Clinical Endocrinology and Metabolism 2004 89 3306-3312.
4. Beshyah SA & Johnston D. Cardiovascular disease and risk factors in adults with hypopituitarism. Clinical Endocrinology 1999 50 1-15.
5. Abdu TA, Neary R, Elhadd TA, Akber M & Clayton RN. Coronary risk in growth hormone deficient hypopituitary adults: increased predicted risk is due largely to lipid profile abnormalities. Clinical Endocrinology 2001 55 209-216.
6. Abs R, Feldt-Rasmussen U, Mattsson AF, Monson JP, Bengtsson B-Å, Góth MI, Wilton P & Koltowska-Häggström M. Determinants of cardiovascular risk in 2589 hypopituitary growth hormone-deficient adults. European Journal of Endocrinology 2006 155 79-90.
7. Sesmilo G, Biller BM, Llevadot J, Hayden D, Hanson G, Rifai N & Klibanski A. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Annals of Internal Medicine 2000 133 111-122.
8. Jørgensen JO, Pedersen SA, Thuesen L, Jørgensen J, Ingemann-Hansen T, Skakkebaek NE & Christiansen JS. Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet 1989 1 1221-1225.
9. Libber SM, Plotnick LP, Johanson AJ, Blizzard RM, Kwiterovich PO & Migeon CJ. Long-term follow-up of hypopituitary patients treated with human growth hormone. Medicine 1990 69 46-55.
10. Abs R, Bengtsson B-Å, Hernberg-Stå E, Monson JP, Tauber J-P, Wilton P & Wüster C. Growth hormone replacement in hypopituitary adults. Demographic, clinical, and dosing characteristics in 1034 patients. Clinical Endocrinology 1999 50 703-713.
11. Beshyah SA, Freemantle C, Thomas E, Rutherford O, Page B, Murphy M & Johnston DG. Abnormal body composition and reduced bone mass in growth hormone deficient hypopituitary adults. Clinical Endocrinology 1995 42 179-189.
12. Mersebach H & Feldt-Rasmussen U. Growth hormone and body composition. Growth hormone deficiency in adults. In Frontiers of Hormonal Research, vol 33, pp 185-195. Eds JOL Jørgensen & JS Christiaensen. Basel: Karger, 2005.
13. Cuneo RC, Salomon F, Watts GF, Hesp R & Sonksen PH. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone deficiency. Metabolism 1993 42 1519-1523.
14. Salomon F, Cuneo RC, Hesp R & Sonksen PH. The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. New England Journal of Medicine 1989 321 1797-1803.
15. Boguszewski CL, Meister LH, Zaninelli DC & Radominski RB. One year of GH replacement therapy with a fixed low-dose regimen improves body composition, bone mineral density and lipid profile of GH-deficient adults. European Journal of Endocrinology 2005 152 67-75.
16. McKenna SP, Doward LC, Alonso J, Kohlmann T, Niero M, Prieto L & Wíren L. The QoL-AGHDA: an instrument for the assessment of quality of life in adults with growth hormone deficiency. Quality of Life Research 1999 8 373-383.
17. Herschbach P, Henrich G, Strasburger CJ, Feldmeier H. Marín F, Attanasio AM & Blum WF. Development and psychometric properties of a disease-specific quality of life questionnaire for adult patients with growth hormone deficiency. European Journal of Endocrinology 2001 145 255-265.
18. Rosilio M, Blum WF, Edwards DJ, Berthezene F, Shavrikova EP, Valle D, Lamberts SWJ, Erfurth EM, Webb SM, Ross RJ, Chihara K, Henrich G, Herschbach P & Attanasio AF. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). Journal of Clinical Endocrinology and Metabolism 2004 89 1684-1693.
19. Koltowska-Häggström M, Mattsson AF, Monson JP, Kind P, Badia X, Casanueva FF, Busschbach J, Koppeschaar HPF & Johannsson G. Does long-term growth hormone replacement therapy in hypopituitary adults with growth-hormone deficiency normalise quality of life? European Journal of Endocrinology 2006 155 109-119.
20. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND & Horan M. Body mass index and the prevalence of hypertension and dyslipidemia. Obesity Research 2000 8 605-619.
21. Douketis JD & Sharma AM. Obesity and cardiovascular disease: pathogenic mechanisms and potential benefits of weight reduction. Seminars in Vascular Medicine 2005 5 25-33.
22. Dixon JB, Dixon ME & O'Brien PE. Quality of life after lap-band placement: influence of time, weight loss, and comorbidities. Obesity Research 2001 9 713-721.
23. Hoffman AR, Kuntze JE, Baptista J, Maum HB, Baumann GP, Biller BM, Clark RV, Cook D, Inzucchi SE, Kleinberg D, Klibanski A, Phil LS, Ridgway EC, Robbins RJ, Schlechte J, Sharma M, Thorner MO & Vance ML. Growth hormone replacement therapy in adult-onset growth hormone deficiency: effects on body composition in men and women in a double-blind, randomised, placebo-controlled trial. Journal of Clinical Endocrinology and Metabolism 2004 89 2048-2056.
24. Abrahamsen B, Nielsen TL, Hangaard J, Gregersen G, Vahl N, Korsholm L, Hansen TB, Andersen M & Hagen C. Dose-, IGF-I- and sex-dependent changes in lipid profile and body composition during GH replacement therapy in adult onset GH deficiency. European Journal of Endocrinology 2004 150 671-679.
25. Gutiérrez LP, Kołtowska-Häggström M, Jönsson PJ, Mattsson AF, Svensson D, Westberg B & Luger A. Registries as a tool in evidence-based medicine: example of KIMS (Pfizer International Metabolic Database). Pharmacoepidemiology and Drug Safety 2008 68 122-129.
26. Friedewald WT, Levy RI & Fredickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clinical Chemistry 1972 18 499-502.
27. Lissett C, Jonsson P, Monson JP & Shalet SM. Determinants of IGF-I status in a large cohort of growth-hormone deficient (GHD) subjects: the role of timing of onset of GHD. Clinical Endocrinology 2003 59 773-778.
28. Russel-Jones DL, Watts GF, Weissberger A, Naoumova RP, Myers J, Thompson GR & Sonksen PH. The effects of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone deficient patients. Clinical Endocrinology 1994 41 345-350.
29. Vahl N, Jorgensen JO, Hansen TB, Klausen IB, Jurik AG, Hagen C & Christiansen JS. The favorable effects of growth hormone substitution on hypercholesterolaemia in GH-deficient adults are not associated with concomitant reductions in adiposity. A 12 month placebo-controlled study. International Journal of Obesity and Related Metabolic Disorders 1998 22 529-536.
30. Hana V, Silha JV, Justova V, Lacinova Z, Stepan JJ & Murphy LJ. The effects of GH replacement in adult GH-deficient patients: changes in body composition without concomitant changes in adipokines and insulin resistance. Clinical Endocrinology 2004 60 442-450.